TABLE 1.
Baseline characteristics of the participants
| All available | Subsample (n = 947) | |
|---|---|---|
| Age (y) | 69.3 ± 4.7 | 69.1 ± 4.7 |
| Female/male (n = 584/667) | 47/53% | 47/53% |
| Education (y) | 10.0 ± 3.4 | 10.0 ± 3.4 |
| Global cognition (z-score) | 0.0 ± 1.0 | 0.06 ± 1.0 |
| Intervention/control group | 50/50% | 48/52% |
| Diabetes (n = 152/1250) | 12% | 13% |
| Cholesterol-lowering drugs (n = 532/1208) | 44% | 46% |
| APOE ≥1 ε-4 (n = 385) | 31% | 31% |
| APOE no ε-4 (n = 781) | 62% | 63% |
| APOE unknown (n = 85) | 7% | 6% |
| BMI (kg/m2; n = 1242) | 28.2 ± 4.7 | 28.2 ± 4.7 |
| Fasting glucose (mmol/L; n = 1248) | 6.1 ± 0.9 | 6.1 ± 0.9 |
| Total cholesterol (mmol/L; n = 1247 | 5.2 ± 1.0 | 5.2 ± 1.0 |
| HDL-C (mmol/L; n = 1247) | 1.4 ± 0.4 | 1.5 ± 0.4 |
| LDL-C (mmol/L; n = 1247) | 3.1 ± 0.9 | 3.1 ± 0.9 |
| Triglycerides (mmol/L; n = 1247) | 1.4 ± 0.6 | 1.4 ± 0.6 |
| ApoA-I (mmol/L; n = 1247) | 1.6 ± 0.3 | 1.6 ± 0.3 |
| ApoB (mmol/L; n = 1247) | 0.9 ± 0.2 | 0.9 ± 0.2 |
| TEI (kJ) | 7810 ± 2277 | 7886 ± 2279 |
| Carbohydrates (E%) | 46.4 ± 7.1 | 46.5 ± 6.9 |
| Total fat (E%) | 32.4 ± 6.4 | 32.4 ± 6.3 |
| Protein (E%) | 16.9 ± 3.1 | 16.9 ± 3.1 |
| Fiber (E%) | 2.3 ± 0.7 | 2.3 ± 0.7 |
| Saturated/total fat (%) | 37.3 ± 6.2 | 37.1 ± 6.1 |
n = 1251, unless stated otherwise. Values as percentages or mean ± SD. The right column shows characteristics of a subsample used for complementary analyses, indicating that differences from the full sample were only marginal. APOE, apolipoprotein E (genotype).